<SEC-DOCUMENT>0001104659-23-036896.txt : 20230327
<SEC-HEADER>0001104659-23-036896.hdr.sgml : 20230327
<ACCEPTANCE-DATETIME>20230327083101
ACCESSION NUMBER:		0001104659-23-036896
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230327
DATE AS OF CHANGE:		20230327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nuvectis Pharma, Inc.
		CENTRAL INDEX KEY:			0001875558
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				862405608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41264
		FILM NUMBER:		23761523

	BUSINESS ADDRESS:	
		STREET 1:		1 BRIDGE PLAZA, SUITE 275
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
		BUSINESS PHONE:		360-837-7232

	MAIL ADDRESS:	
		STREET 1:		1 BRIDGE PLAZA, SUITE 275
		CITY:			FORT LEE
		STATE:			NJ
		ZIP:			07024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>tm2310472d1_10ka.htm
<DESCRIPTION>FORM 10-K/A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:nvct="http://nuvectis.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_nvct_nuvectis.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001875558 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DDocumentFiscalYearFocus_2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0001875558</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nvct-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875558</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875558</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875558</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C.&#160;20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20220101__20221231_zQpbYJ6pfOd1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">10-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amendment No.&#160;1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="font-family: Wingdings"><span id="xdx_908_edei--DocumentAnnualReport_c20220101__20221231_zOCtc1joYk9i"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#120;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt">ANNUAL
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Fiscal&#160;Year Ended <span id="xdx_900_edei--DocumentPeriodEndDate_c20220101__20221231_ztbpr2CkIQrk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>or</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="font-family: Wingdings"><span id="xdx_900_edei--DocumentTransitionReport_c20220101__20221231_zZ1JvrnnFpI3"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#168;</ix:nonNumeric></span></span></b><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></span><b><span style="font-size: 10pt">TRANSITION
REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Transition Period from <span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;&#160;&#160;to
<span style="text-decoration: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#160;&#160;&#160;.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number <span id="xdx_903_edei--EntityFileNumber_c20220101__20221231_zq3plQgZhxah"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityFileNumber">001-41264</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20220101__20221231_zvicvALtoejk"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">NUVECTIS PHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20220101__20221231_zcUKulOGxua6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20220101__20221231_zX3A7DeLnNj5"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityTaxIdentificationNumber">86-2405608</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of Incorporation or Organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20220101__20221231_zd320d8puF95"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine1">1 Bridge Plaza</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20220101__20221231_zJQh8Zfa4Sw8"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressAddressLine2">Suite
    275</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20220101__20221231_zZ7oBbKrcjZi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressCityOrTown">Fort Lee</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20220101__20221231_z9KAmXk2lOR"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span> 07024</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20220101__20221231_z67BHt2guIv2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityAddressPostalZipCode">07024</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_900_edei--CityAreaCode_c20220101__20221231_zKdk6EbW2ntb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:CityAreaCode">201</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20220101__20221231_zbEzDOJeyMT2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:LocalPhoneNumber">614-3150</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid; text-align: center; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20220101__20221231_zQgBcRX71021"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:Security12bTitle">Common Stock, par value $0.00001 per</ix:nonNumeric></span></b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20220101__20221231_znOB3HS6kWMi"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:TradingSymbol">NVCT</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--SecurityExchangeName_c20220101__20221231_z6Zy2S6zmlZg"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities registered pursuant to section 12(g)&#160;of
the Act: None.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span>&#160;&#160;<span id="xdx_903_edei--EntityWellKnownSeasonedIssuer_c20220101__20221231_z8WWGZe8CmDf"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#120;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes&#160;&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span>&#160;&#160;<span id="xdx_90C_edei--EntityVoluntaryFilers_c20220101__20221231_zNPWkwHd0L87"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#120;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities
Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports),
and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20220101__20221231_z3xSPVZmnEYa"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Wingdings">&#120;</span></span>&#160;&#160;No&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405
of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20220101__20221231_zBm8jo2qXV12"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Wingdings">&#120;</span></span>&#160;&#160;No&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td>
    <td style="width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings">&#168;</span></span></td>
    <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings">&#168;</span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20220101__20221231_zScy9lBGWtGd"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings">&#120;</span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--EntitySmallBusiness_c20220101__20221231_zhTzcuoKiVyl"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#120;</ix:nonNumeric></span></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20220101__20221231_zrvyoE0Fezk2"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityExTransitionPeriod_c20220101__20221231_zPCDoaQAxWL9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. <span style="font-family: Wingdings"><span id="xdx_904_edei--IcfrAuditorAttestationFlag_c20220101__20221231_zbdGAIoHwjn9"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section&#160;12(b)&#160;of
the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an
error to previously issued financial statements. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;&#160;&#160;<span style="font-family: Wingdings">&#168;</span></span>&#160;&#160;<span id="xdx_901_edei--EntityShellCompany_c20220101__20221231_zk5NAqizWzae"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="font-family: Wingdings">&#120;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&#160;30, 2022, the last business
day of the registrant&#8217;s most recently completed fiscal&#160;year, the aggregate market value of the registrant&#8217;s common stock
held by non-affiliates was approximately $<span id="xdx_900_edei--EntityPublicFloat_iI_pn5n6_c20221230_zFGYMr97mwkk"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2022-12-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">64.0</ix:nonFraction></span> million, based on the closing sale price of $7.50 as quoted by the Nasdaq Stock Market
as of such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of shares outstanding of each
of the registrant&#8217;s classes of common stock, as of the latest practicable date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class&#160;of Common Stock</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding Shares as of March&#160;22, 2023</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.00001 par value</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20230322_z7BBNJctUwy2"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-03-22" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,752,403</ix:nonFraction></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Auditor name: <span id="xdx_902_edei--AuditorName_c20220101__20221231_z2WSKUJU0Rsb"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorName">PricewaterhouseCoopers International Limited</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Auditor Location: <span id="xdx_900_edei--AuditorLocation_c20220101__20221231_zwkjazj6EUP6"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorLocation">Tel-Aviv, Israel</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Auditor Firm ID: <span id="xdx_906_edei--AuditorFirmId_c20220101__20221231_zSTYvNDjq2Ea"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AuditorFirmId">1309</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&#160;1
(&#8220;Amendment No.&#160;1&#8221;) to the Annual Report on Form&#160;10-K of Nuvectis Pharma,&#160;Inc. (the &#8220;Company,&#8221;
 &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) for the fiscal year ended December&#160;31, 2022 as filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;8, 2023 (the &#8220;Original Annual Report&#8221;), is being filed to include
in the Original Annual Report the information required by Part&#160;III (Items 10, 11, 12, 13 and 14) of Form&#160;10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No.&#160;1
amends and restates in their entirety Items 10 through 14 of the Original Annual Report. As required by Rule&#160;12b-15 under the Securities
and Exchange Act of 1934, as amended, new certificates of our chief executive officer and chief financial officer are being filed as exhibits
to this Amendment No.&#160;1. Accordingly,&#160;Item 15(a)(3)&#160;of Part&#160;IV is amended to include the currently dated certifications
as exhibits. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend
any disclosure with respect to Items&#160;307&#160;and&#160;308&#160;of&#160;Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. &#160;In addition, because no financial statements are included in this Amendment No.&#160;1, new certifications of
the Company&#8217;s Chief Executive Officer and Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002
are not required to be included with Amendment No.&#160;1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise expressly
noted herein, this Amendment No.&#160;1 does not amend any other information set forth in the Original Annual Report, and we have not
updated disclosures contained therein to reflect any events that occurred at a date subsequent to the date of the filing of the Original
Annual Report. Accordingly, this Amendment No.&#160;1 should be read in conjunction with the Original Annual Report and our other filings
with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No.&#160;1 have the meanings given to them in
the Original Annual Report.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p></div>
    <!-- Field: /Page -->
<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NUVECTIS PHARMA,&#160;INC.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS<sup></sup></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom; width: 10%">&#160;</td>
    <td style="vertical-align: bottom; width: 84%">&#160;</td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#har_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;III</b></span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_001">4</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive
    Officers and Corporate Governance</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_002">4</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#har_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_003">10</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of
    Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_004">16</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#har_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships
    and Related Transactions, and Director Independence</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_005">18</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant
    Fees and Services</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_006">19</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;IV</b></span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_007">20</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#har_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial
    Statement Schedules</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_008">20</a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</span></a></td>
    <td style="vertical-align: bottom"><a href="#har_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;10-K Summary</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_009">21</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#har_010">Signatures</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><a href="#har_010">22</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="har_001"></span>PART&#160;III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;10.</b></span><b><span id="har_002"></span>&#160;&#160;&#160;Directors,
Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following biographies set forth the names
of our current directors and executive officers, their ages, their positions with us, their principal occupations and employers, any
other directorships held by them during the past five years in companies that are subject to the reporting requirements of the Securities
Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), or any company registered as an investment company under the Investment Company
Act of 1940, as well as additional information, all of which we believe sets forth each director nominee&#8217;s qualifications to serve
on the Board. There is no family relationship between and among any of our executive officers or directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information about our directors
and executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8203;</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8203;</b></span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 4%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8203;</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8203;</b></span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 76%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
    Bentsur</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Chief Executive Officer and President</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrique Poradosu</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President,
    Chief Scientific and Business Officer</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shay
    Shemesh</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice President, Chief Development and Operations Officer</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Carson</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Finance</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Hoberman</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;58
    </span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Kaplan</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;55
    </span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    F. Oliviero</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;47
    </span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8203;</span></td>
    <td style="white-space: nowrap; background-color: #CCEEFF"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers and Senior Management</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ron Bentsur</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Bentsur has served
on our Board since inception and has 20&#160;years of senior leadership experience in the biotechnology industry. He served as CEO of
UroGen Pharma,&#160;Inc. (NASDAQ: URGN) from August&#160;2015 until January&#160;2019, and as CEO of Keryx Biopharmaceuticals,&#160;Inc.
(NASDAQ: KERX, acquired by Akebia Therapeutics) from May&#160;2009 until May&#160;2015. At UroGen and Keryx, Mr.&#160;Bentsur led the
clinical development, regulatory approvals and the commercial infrastructure buildouts for the US commercial launches of Jelmyto and
Auryxia, respectively. Mr.&#160;Bentsur also led the establishment of a successful worldwide partnership for an earlier-stage program
at UroGen and an ex-US development partnership for Auryxia at Keryx. Mr.&#160;Bentsur served as CEO of XTL Biopharmaceuticals,&#160;Inc.
(NASDAQ: XTLB) from January&#160;2006 until April&#160;2009 and as Investor Relations and CFO of Keryx from October&#160;2000 until January&#160;2006.
Mr.&#160;Bentsur worked as an investment banker in NYC and Tel Aviv,&#160;Israel, from 1994 until 2000. Mr.&#160;Bentsur served as a
member of the Board of Directors of Stemline Therapeutics,&#160;Inc. from 2009 through the approval and launch of Elzonris&#174; and through
the subsequent acquisition of the company by Menarini in June&#160;2020, and serves on the Board of Directors of Beyond Air,&#160;Inc.
(NASDAQ: XAIR). Mr.&#160;Bentsur holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem,&#160;Israel
and an MBA (<i>Magna Cum Laude</i>), from New York University&#8217;s Stern School of Business. Mr.&#160;Bentsur has been selected to
serve on our Board of Directors based on his&#160;years of experience in the biotechnology industry and extensive management experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Enrique Poradosu, PhD</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&#160;Poradosu has 20
years of senior scientific leadership experience in the biotechnology industry and has served as our Executive Vice President, Chief
Scientific and Business Officer since our inception. From January&#160;2016 until December&#160;2020, he served as SVP, Business and
Scientific Strategy at Stemline Therapeutics,&#160;Inc. (NASDAQ: STML, acquired by Menarini in June&#160;2020). At Stemline Dr.&#160;Poradosu
led the licensing and scientific strategy of the company&#8217;s pipeline, as well as directly leading strategic planning and operational
execution of the early-stage drug development programs. Prior to that, Dr.&#160;Poradosu served as VP Business and Scientific Strategy
at Keryx Biopharmaceuticals,&#160;Inc. (NASDAQ: KERX), acquired by Akebia Therapeutics (NASDAQ: AKBA)), from 2003 until 2016. From 1998
until 2003, Dr.&#160;Poradosu served as a project manager at a private biomedical incubator. Dr.&#160;Poradosu holds a BSc in Chemistry
and Biology with distinction from the Hebrew University of Jerusalem,&#160;Israel and a PhD in Biochemistry, from the Hebrew University
of Jerusalem.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shay Shemesh</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Shemesh has 15 years
of multi-disciplinary experience in drug development and has served as our Executive Vice President and Chief Development Officer since
our inception. From 2015 until 2020, he served as SVP, Clinical and Regulatory Affairs at Stemline Therapeutics,&#160;Inc. (NASDAQ: STML,
acquired by Menarini in June&#160;2020) where he led multi-disciplinary development teams in early and late-stage projects. In this role,
Mr.&#160;Shemesh held responsibilities for the strategic planning and operational execution of the Elzonris&#174;&#160;Biologics License
Application, with the FDA and Marketing Authorization Application with EMA, resulting in the approval of Elzonris&#8482; in both regions
for the treatment of blastic plasmacytoid dendritic cell neoplasm, an orphan hematologic malignancy. Prior to that, Mr.&#160;Shemesh
was lead of clinical operations at Keryx Biopharmaceuticals (NASDAQ: KERX, acquired by Akebia Therapeutics (NASDAQ: AKBA)), where he
managed the late-stage clinical trials for Auryxia&#8482; for the treatment of anemia in patients with non-dialysis CKD, which led to
the approval of Auryxia in this indication in the US and the EU. Mr.&#160;Shemesh holds a BSc and MSc in Biotechnology from Bar Ilan
University in Israel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Michael Carson</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Carson has over
20 years of broad experience in corporate finance, accounting, and operations. He specializes in clinical stage biopharmaceutical and
biotechnology companies. From late 2019 until 2021, he served as Vice President of Finance at XyloCor Therapeutics,&#160;Inc. where he
led the accounting, treasury and finance functions. During 2019, Mr.&#160;Carson consulted for Smiths Medical,&#160;Inc., a division
of Smiths Group, as Global Controller along with serving as Vice President of Finance in a consulting role for several other biopharmaceutical
and medical device companies. At Smiths Medical, he led a team responsible for accounting, treasury and foreign currency exposure. From
2015 to 2019 he served as Director of Financial Planning and Analysis at Neuronetics (NASDAQ: STIM). In this role, Mr.&#160;Carson served
as the second in command to the Chief Financial Officer and held responsibilities for strategic planning, financial execution, investor
relations, and controllership. In the past, he has held several finance and accounting positions at Abbott Laboratories (NYSE: ABT) and
served as an auditor at Crowe LLP and Deloitte. Mr.&#160;Carson holds a Bachelor of Arts in Business and Economics along with a Bachelor
of Science in Mechanical Engineering from Lafayette College in Pennsylvania. He is a licensed Certified Public Accountant in the Commonwealth
of Pennsylvania.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-Employee Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Kenneth Hoberman</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Hoberman joined
our Board of Directors in July&#160;2021. Mr.&#160;Hoberman has extensive financial, investor relations, corporate governance, operational,
and business development experience including M&amp;A, strategic alliances and partnerships both domestic and international. Mr.&#160;Hoberman
has served as the Chief Operating Officer of Stemline Therapeutics,&#160;Inc. (&#8220;Stemline&#8221;) since 2013, where he negotiated
and closed several licensing agreements and was responsible for multiple vendor contracts. While at Stemline, he helped lead the company
from an early-stage drug development company to a fully integrated commercial entity, including through Stemline&#8217;s successful initial
public offering. Mr.&#160;Hoberman directed all Stemline&#8217;s functional groups, including manufacturing, commercial, regulatory,
R&amp;D, medical affairs, public and investor relations, HR and finance. Mr.&#160;Hoberman also led the M&amp;A transaction which resulted
in the sale of Stemline to the Menarini Group in June&#160;2020 for approximately $750 million. He was previously Vice President of Corporate
and Business Development of Keryx Biopharmaceuticals,&#160;Inc., where he initiated and executed a Japanese partnership valued at up
to $100&#160;million, and originated, negotiated and closed dozens of licensing and operational contracts, including the licensing of
Auryxia&#8482;, which was approved by the FDA in September&#160;2014. He is on the Board of Directors of TG Therapeutics,&#160;Inc. (Nasdaq:
TGTX). He received a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University. Mr.&#160;Hoberman
has been selected to serve on our Board of Directors based on his extensive experience in the biopharmaceutical industry and in-depth
understanding of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Matthew Kaplan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Kaplan joined our
Board of Directors in September&#160;2021. Mr.&#160;Kaplan is an experienced Equity Analyst with deep knowledge in biotechnology, particularly
for analysis and advisement of early-stage companies. With 24 years of experience as an Equity Analyst, since 2008, he has been a Managing
Director and the Head of Healthcare Equity Research at Ladenburg Thalmann&#160;&amp; Co. Prior to joining Ladenburg Thalmann&#160;&amp;
Co., he was a Partner and the Director of Healthcare Research with Punk, Ziegel&#160;&amp; Company, a Senior Biotechnology Analyst at
Evolution Capital, and a Director of The Life Sciences Group at The Carson Group. Mr.&#160;Kaplan has received numerous citations as
a top ranked Biotechnology Stock Picker by Thomson Reuters, The Financial Times, and Forbes. Mr.&#160;Kaplan also spent six years as
a Research Associate with the Albert Einstein College of Medicine / Montefiore Hospital Department of Cardiology, where he co-authored
numerous articles on gene regulation in the heart. Mr.&#160;Kaplan received his BS in Biology from the University of Michigan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>James F. Oliviero,&#160;III</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Oliviero joined
our Board of Directors in July&#160;2021. Mr.&#160;Oliviero has over twenty&#160;years of operational experience in the biotechnology
industry. Since 2015, Mr.&#160;Oliviero has served as the President and Chief Executive Officer of Checkpoint Therapeutics,&#160;Inc.
(NASDAQ: CKPT), where he has completed over $100&#160;million in private and public financings for the company to date, while designing
and overseeing the company&#8217;s development programs for its novel immuno-oncology and targeted therapy, a type of cancer treatment
that precisely identifies and attacks a specific pathway of cancer cells, product candidates being evaluated for the treatment of several
solid tumor cancer indications. Prior to Checkpoint, from May&#160;2003 to September&#160;2015, Mr.&#160;Oliviero served in a variety
of leadership capacities at Keryx Biopharmaceuticals,&#160;Inc., which was subsequently acquired by Akebia. His most recent position
at Keryx, beginning in April&#160;2009, was as Chief Financial Officer, responsible for all of the finance, accounting, investor relations,
corporate governance and legal matters and was also involved in the clinical and regulatory development of Auryxia&#174;, which successfully
obtained FDA approval in 2014. From August&#160;1999 to May&#160;2003, Mr.&#160;Oliviero was Director of Finance for ACCESS Oncology,&#160;Inc.,
a privately held biotechnology company. Mr.&#160;Oliviero began his professional career as an investment banker at Furman Selz LLC in
New York City. Mr.&#160;Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University&#8217;s
Goizueta Business School. Mr.&#160;Oliviero has been selected to serve on our Board of Directors based on his extensive experience in
the biotechnology industry and in-depth understanding of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Election of Officers and Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive officers are
appointed by, and serve at the discretion of, our board of directors. There are no family relationships among any of our directors or
executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Composition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws provide that our
board of directors shall consist of between one and nine directors, which number shall be fixed from time to time by resolution of our
board of directors. Currently our board of directors consists of Ron Bentsur, Kenneth Hoberman, James Oliviero, and Matthew Kaplan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our bylaws also provide that
our directors may be removed with or without cause by the affirmative vote of the holders of at least two-thirds of the votes that all
our stockholders would be entitled to cast in an annual election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current and future executive
officers and significant employees serve at the discretion of our Board. Our Board may also choose to form certain committees, such as
a compensation committee and an audit committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that Kenneth Hoberman, Matthew Kaplan and James Oliviero are independent directors. In making this determination, our board
of directors applied the standards set forth in the rules&#160;of Nasdaq and in Rule&#160;10A-3 under the Exchange Act. Our board of
directors considered all relevant facts and circumstances known to it in evaluating the independence of these directors, including their
current and historical employment, any compensation we have given to them, any transactions we have with them, their beneficial ownership
of our capital stock, their ability to exert control over us, all other material relationships they have had with us and the same facts
with respect to their immediate families.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although there is no specific
policy regarding diversity in identifying director nominees, the board of directors seek the talents and backgrounds that would be most
helpful to us in selecting director nominees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Leadership Structure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Ron Bentsur, our
Chief Executive Officer, is also the Chairman of our board of directors. Our corporate governance guidelines provide our board of directors
with flexibility to select the appropriate leadership structure at a particular time based on what our board of directors determines
to be in the best interests of the Company. Our board of directors determined that, at the present time, having our Chief Executive Officer
also serve as the Chairman of our board of directors provides us with optimally effective leadership and is in our best interests and
those of our stockholders. Twenty years of management experience in our industry as well as his extensive understanding of our business,
operations, and strategy make him well qualified to serve as chairman of our board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Oversight of Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Risk assessment and oversight
are an integral part of our governance and management processes. Our board of directors encourages management to promote a culture that
incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational
risks at regular management meetings and conducts specific strategic planning and review sessions during the year that include a focused
discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the board of directors
at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies,
and presents the steps taken by management to mitigate or eliminate such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors does
not have a standing risk management committee, but rather administers this oversight function directly through our board of directors
as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective
areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure. Our audit
committee is responsible for coordinating the board of director&#8217;s oversight of our internal control over financial reporting, disclosure
controls and procedures, related-party transactions and code of conduct and corporate governance guidelines. Our compensation committee
is responsible for assessing and monitoring whether any of our compensation policies and programs has the potential to encourage excessive
risk-taking as well as succession planning as it relates to our Chief Executive Officer. While each committee is responsible for evaluating
certain risks and overseeing the management of such risks, our entire board of directors will be regularly informed through committee
reports about such risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
established an audit committee and compensation committee, each of which operates pursuant to a charter adopted by our board of directors.
Our board of directors may also establish other committees from time to time to assist the management of our business. The composition
and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined
by our board of directors. Each committee already established has adopted a written charter that will satisfy the applicable rules&#160;and
regulations of the Sarbanes-Oxley Act, the SEC and Nasdaq Listing Rules, which is available on our website at www.nuvectis.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee consists
of Kenneth Hoberman, Matthew Kaplan and James Oliviero, with James Oliviero serving as chair. Our board of directors has determined that
each member of the audit committee has sufficient knowledge in financial and auditing matters to serve on the Audit Committee. Our board
of directors has determined James Oliviero qualifies as an &#8220;audit committee financial expert,&#8221; as defined under the applicable
rules&#160;of the SEC. In making this determination, our board has considered prior experience, business acumen and independence. The
audit committee&#8217;s responsibilities include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating the performance,
    independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or
    engage new independent auditors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring the rotation
    of partners of our independent auditors on our engagement team as required by law;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to engagement of
    any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their
    independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our annual and
    quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion
    and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent
    auditors and management;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, with our independent
    auditors and management, significant issues that arise regarding accounting principles and financial statement presentation and matters
    concerning the scope, adequacy and effectiveness of our financial controls;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with management
    and our independent auditors any earnings announcements and other public announcements regarding material developments;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures
    for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters
    and other matters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the report that
    the SEC requires in our annual proxy statement;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and providing
    oversight of any related-person transactions in accordance with our related-person transaction policy and reviewing and monitoring
    compliance with legal and regulatory responsibilities, including our code of business conduct and ethics;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing our major financial
    risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management are implemented;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing on a periodic
    basis our investment policy; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and evaluating
    on an annual basis the performance of the audit committee and the audit committee charter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our compensation committee consists of Kenneth
Hoberman, Matthew Kaplan and James Oliviero, with Kenneth Hoberman serving as chair. Our board of directors has determined that each
of the members of our compensation committee is a non-employee director, as defined in Rule&#160;16b-3 promulgated under the Exchange
Act, and satisfies the Nasdaq independence requirements. The functions of this committee include, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    our philosophy, policies and plans with respect to the compensation of our chief executive officer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations
    to our board of directors with respect to the compensation of our chief executive officer and our other executive officers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and assessing
    the independence of compensation advisors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and administering
    our equity incentive plans;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations
    to our board of directors with respect to director compensation; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the Compensation
    Committee reports required by the SEC, including our &#8220;Compensation Discussion and Analysis&#8221; disclosure.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the composition
and functioning of our compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act, and all applicable
SEC and Nasdaq rules&#160;and regulations. We intend to comply with future requirements to the extent they become applicable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Nominating and Corporate Governance Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors does
not currently have a nominating and corporate governance committee or other committee performing a similar function, nor do we have any
formal written policies outlining the factors and process relating to the selection of nominees for consideration for membership on our
board of directors by our directors or our stockholders. Our board of directors has adopted resolutions in accordance with the rules&#160;of
The Nasdaq Stock Market authorizing a majority of our independent members to recommend qualified director nominees for consideration
by the board of directors. Our board of directors believes that it is appropriate for us to not have a standing nominating and corporate
governance committee because of a number of factors, including the number of independent members who want to participate in consideration
of candidates for membership on our board of directors and in matters that relate to the corporate governance of our company. Our board
of directors consists of four members, three of whom are independent. Our board of directors considered forming a nominating and corporate
governance committee consisting of several of the independent members of our board of directors. Forming a committee consisting of less
than all of the independent members was unattractive because it would have omitted the other independent members of our board of directors
who wanted to participate in considering qualified candidates for board membership and to have input on corporate governance matters
related to our company. Since our board of directors desired the participation in the nominations process of all of its independent directors,
it therefore decided not to form a nominating and corporate governance committee and instead authorized a majority of the independent
members of our board of directors to make and consider nominations for membership to our board of directors. The independent members
of our board of directors do not have a nominating and corporate governance committee charter, but act pursuant to board of director
resolutions as described above. Each of the members of our board of directors authorized to recommend director nominees is independent
within the meaning of the current &#8220;independent director&#8221; standards established by The Nasdaq Stock Market rules. Our board
of directors intends to review this matter periodically, and may in the future elect to designate a formal nominating and corporate governance
committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a written code of business conduct, that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of
the code is available on our website at&#160;</span><span style="text-decoration: underline">www.nuvectis.com</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Delinquent Section&#160;16(a)&#160;Reports</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&#160;16(a)&#160;of
the Exchange Act requires our directors, executive officers and persons who own more than 10% of the shares of our common stock to file
an initial report of ownership on Form&#160;3 and changes in ownership on Form&#160;4 or Form&#160;5 with the SEC. Such officers, directors
and 10% stockholders are also required by SEC rules&#160;to furnish us with copies of any Forms 3, 4 or 5 that they file. The SEC rules&#160;require
us to disclose late filings of initial reports of stock ownership and changes in stock ownership by our directors, executive officers
and 10% stockholders. Based solely on a review of copies of the Forms 3, 4 and 5 furnished to us by reporting persons and any written
representations furnished by certain reporting persons, we believe that during the fiscal year ended December&#160;31, 2022, all Section&#160;16(a)&#160;filing
requirements applicable to our directors, executive officers and 10% stockholders were completed in a timely manner with the exception
of Ron Bentsur. Mr.&#160;Bentsur filed 5 late reports on Form&#160;4, and each late report represented one transaction that was not reported
on a timely basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;11.</b></span><b><span id="har_003"></span>&#160;&#160;&#160;Executive
Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information concerning compensation paid by us to Mr.&#160;Bentsur, Dr.&#160;Poradosu, and Mr.&#160;Shemesh, our &#8220;named executive
officers,&#8221; for their services rendered to us in all capacities during the years ended December&#160;31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    and<br />
    Principal <br />
    Position</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Salary ($)&#160;&#160;&#160;&#160;</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br />
    &#160;&#160;($)&#160;</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br />
    Awards<br /> ($)<sup>(1)(2)</sup></b></span><b>&#160;&#160;</b></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    Other<br />
    Compensation<br /> ($)</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br />
    ($)</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 22%; text-align: left">Ron Bentsur</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">420,360</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">431,250</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">(3)&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">842,400</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">1,694,010</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">President, Chief</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2021</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">384,018</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">384,018</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Executive Officer and Director</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Enrique Poradosu</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">349,072</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200,000</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">421,200</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">970,272</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Chief Scientific&#160;&amp; Business
    Officer</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2021</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,083</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">192,056</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font-size: 10pt; text-align: right">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">219,139</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Shay Shemesh</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2022</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">329,268</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200,000</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">(3)&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">421,200</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">950,468</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in">Chief Development&#160;&amp; Operations
    Officer</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2021</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27,083</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">192,056</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">219,139</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Reflects
the aggregate grant date fair value of equity awards granted during the fiscal year calculated in accordance with FASB ASC Topic 718.
Refer to Note 7 in the Notes to the Financial Statements included in our Original Annual Report on Form&#160;10-K for the year ended December&#160;31,
2022 for information regarding the assumptions used to value these awards. The grant date fair value of the equity awards does not take
into account any awards which vest upon certain corporate milestones when the &#8220;measurement date&#8221; for accounting purposes for
such awards has not yet occurred and the fair value is uncertain. For such awards, stock-based compensation is measured and recorded if
and when a milestone occurs, and the compensation for such awards are reflected in the table in such year the compensation is recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) As
per their employment contracts, in 2021, Mr.&#160;Bentsur, Dr.&#160;Poradosu, and Mr.&#160;Shemesh were granted 96,759, 48,399, and 48,399
shares of restricted stock, respectively, related to a certain milestone. This milestone was met on July&#160;27, 2022 and these shares
will vest on June&#160;30, 2023. In addition, Mr.&#160;Bentsur, Dr.&#160;Poradosu, and Mr.&#160;Shemesh were granted 120,000, 60,000,
and 60,000 restricted stock units, respectively, upon the completion of the Company&#8217;s Initial Public Offering (&#8220;IPO&#8221;)
which will vest in thirds on the next three anniversaries of the grant date, April&#160;1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Reflects a bonus award earned upon the completion
of the Company&#8217;s IPO which has not been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative to Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following are our employment arrangements
with our named executive officers:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ron Bentsur</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Base Salary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;4, 2022,
we entered into an employment agreement with Mr.&#160;Bentsur, pursuant to which he receives an initial annual base salary of $575,000,
paid monthly in equal installments. On an annual basis, the amount of Mr.&#160;Bentsur&#8217;s salary shall be increased by no less than
the greater of (1)&#160;the amount determined by the Company&#8217;s Compensation Committee, or (2)&#160;the relevant consumer price
index (&#8220;CPI&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Bonus</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Mr.&#160;Bentsur received a bonus of $431,250 related to the
completion of the Company&#8217;s IPO which has not been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Equity Award</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Bentsur is eligible
for grants of equity awards under the Company&#8217;s long-term equity incentive plan. In 2022, the Company awarded 120,000 restricted
stock units to Mr.&#160;Bentsur which will vest in thirds on each of the next three anniversaries of the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Termination Provisions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that Mr.&#160;Bentsur
is terminated without Cause, for Good Reason, upon a Change of Control &#8220;<i>Transaction</i>&#8221; &#8203;(as
such term is defined in the Company&#8217;s Global Equity Incentive Plan, as amended from time to time, or a successor plan), Death or
Disability, as each such term is defined in Mr.&#160;Bentsur&#8217;s employment agreement, all unvested shares of restricted stock and
options shall be immediately accelerated and become fully vested and unrestricted/&#8203;exercisable. Upon termination
for Cause, all unvested shares of restricted shock shall expire and terminate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Mr.&#160;Bentsur resigns
for Good Reason or is terminated due to Death or Disability, Change of Control, or otherwise terminated without Cause, then Mr.&#160;Bentsur
or his estate or beneficiaries, in the case of Death or Disability, will receive a one-time payment equal to two years of Mr.&#160;Bentsur&#8217;s
then annual base salary, plus a bonus payment equal to the annual bonus earned in the preceding year (if not already paid), the pro rata
portion of the target bonus earned in the current year, benefits and expense reimbursement due to Mr.&#160;Bentsur, payment in lieu of
any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the longest applicable limitations
period under the Company&#8217;s directors and officers insurance policies, all such payments to be made within 60 days of the date of
termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above
the Company may terminate Mr.&#160;Bentsur&#8217;s employment at any time, immediately, for Cause, upon written notice to Mr.&#160;Bentsur.
If Mr.&#160;Bentsur&#8217;s employment is terminated for Cause, he shall be entitled to receive (i)&#160;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment, and (ii)&#160;payment for any unused vacation
days which have accrued through the effective date of the termination of Mr.&#160;Bentsur&#8217;s employment, in each case to be paid
within 30 days after such effective date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a &#8220;<i>Transaction</i>&#8221;
occurs during Mr.&#160;Bentsur&#8217;s employment, regardless of whether Mr.&#160;Bentsur&#8217;s employment is terminated, Mr.&#160;Bentsur
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Mr.&#160;Bentsur shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&#160;any accrued benefits upon any such subsequent termination,
and (ii)&#160;cash payments, paid in periodic installments in accordance with the Company&#8217;s usual payroll practices, for a period
of 18 months, equal to the cost the Company would have incurred had Mr.&#160;Bentsur continued group medical, dental, vision and/or prescription
drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering Mr.&#160;Bentsur
and his eligible dependents at the time of the termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Enrique Poradosu</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Base Salary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February&#160;4, 2022, we entered into an employment agreement with Dr.&#160;Poradosu, pursuant to which he received an initial annual
base salary is $400,000, paid monthly in equal installments. </span>On April&#160;1, 2022, the Compensation Committee increased Dr.&#160;Poradosu&#8217;s
base salary to $425,000. On an annual basis, the amount of Dr.&#160;Poradosu&#8217;s salary shall be increased by no less than the greater
of (1)&#160;the amount determined by the Company&#8217;s Compensation Committee, or (2)&#160;the relevant CPI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Bonus</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Dr.&#160;Poradosu received a bonus of $200,000 related to
the completion of the Company&#8217;s IPO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Equity Awards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&#160;Poradosu is eligible
for grants of equity awards under the Company&#8217;s long-term equity incentive plan. In 2022, the Company awarded 60,000 restricted
stock units to Dr.&#160;Poradosu which vest one third on each of the next three anniversaries of the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Termination Provisions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that Dr.&#160;Poradosu
is terminated without Cause, for Good Reason, upon a Change of Control &#8220;<i>Transaction</i>&#8221; &#8203;(as
such term is defined in the Company&#8217;s Global Equity Incentive Plan, as amended from time to time, or a successor plan), Death or
Disability (as such terms are defined in Dr.&#160;Poradosu&#8217;s employment agreement) all unvested shares of restricted stock and
options shall be immediately accelerated and become fully vested and unrestricted/&#8203;exercisable. Upon termination
for Cause, all unvested shares of restricted shock shall expire and terminate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Dr.&#160;Poradosu resigns
for Good Reason or is terminated due to Death or Disability, Change of Control, or otherwise terminated without Cause, Dr.&#160;Poradosu
or his estate or beneficiaries, in the case of Death or Disability, will receive a one-time payment equal to two years of Dr.&#160;Poradosu&#8217;s
then annual Base Salary, plus a bonus payment equal to Dr.&#160;Poradosu&#8217;s annual bonus earned in the preceding year if not already
paid, the pro rata portion of the target bonus earned in the current year, benefits and expense reimbursement due to Dr.&#160;Poradosu,
payment in lieu of any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the longest
applicable limitations period under the Company&#8217;s directors and officers insurance policies, all such payments to be made within
60 days of the date of termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above
the Company may terminate Dr.&#160;Poradosu&#8217;s employment at any time, immediately, for Cause, upon written notice to Dr.&#160;Poradosu.
If Dr.&#160;Poradosu&#8217;s employment is terminated for Cause, he shall be entitled to receive (i)&#160;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment, and (ii)&#160;payment for any unused vacation
days which have accrued through the effective date of the termination of his employment, in each case to be paid within 30 days after
such effective date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a &#8220;<i>Transaction</i>&#8221;
occurs during Dr.&#160;Poradosu&#8217;s employment, regardless of whether Dr.&#160;Poradosu&#8217;s employment is terminated, Dr.&#160;Poradosu
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Dr.&#160;Poradosu shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&#160;any accrued benefits upon any such subsequent termination,
and (ii)&#160;cash payments, paid in periodic installments in accordance with the Company&#8217;s usual payroll practices for a period
of 18 months, equal to the cost the Company would have incurred had Dr.&#160;Poradosu continued group medical, dental, vision and/or
prescription drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering
Dr.&#160;Poradosu and his eligible dependents at the time of the termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Shay Shemesh</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Base Salary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February&#160;4, 2022, we entered into an employment agreement with Mr.&#160;Shemesh, pursuant to which he received an initial annual
base salary of $400,000, paid monthly in equal installments. </span>On April&#160;1, 2022, the Compensation Committee increased Mr.&#160;Shemesh&#8217;s
base salary to $425,000. On an annual basis, the amount of the Mr.&#160;Shemesh&#8217;s Salary shall be increased by no less than the
greater of (1)&#160;the amount determined by the Company&#8217;s Compensation Committee, or (2)&#160;the relevant CPI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Annual Bonus</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Mr.&#160;Shemesh received a bonus of $200,000 related to the
completion of the Company&#8217;s IPO which has not been paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Equity Awards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&#160;Shemesh is eligible
for grants of equity awards under the Company&#8217;s long-term equity incentive plan. In 2022, the Company awarded 60,000 restricted
stock units to Mr.&#160;Shemesh which vest one third on each of the next three anniversaries of the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Termination Provisions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that Mr.&#160;Shemesh
is terminated without Cause, for Good Reason, upon a Change of Control &#8220;<i>Transaction</i>&#8221; &#8203;(as
such term is defined in the Company&#8217;s Global Equity Incentive Plan, as amended from time to time, or a successor plan), Death or
Disability (as such terms are defined in the employment agreement) all unvested shares of restricted stock and options shall be immediately
accelerated and become fully vested and unrestricted/exercisable. Upon termination for Cause, all unvested shares of restricted shock
shall expire and terminate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Mr.&#160;Shemesh resigns
for Good Reason or is terminated due to Death or Disability, Change of Control, or otherwise terminated without Cause, then Mr.&#160;Shemesh
or his estate or beneficiaries, in the case of Death or Disability, will receive a one-time payment equal to two years of Mr.&#160;Shemesh&#8217;s
then annual Base Salary, plus a bonus payment equal to the annual bonus earned in the preceding year if not already paid, the pro rata
portion of the target bonus earned in the current year, plus benefits and expense reimbursement due to Mr.&#160;Shemesh, payment in lieu
of any accrued but unused vacation time, payment of any unreimbursed expenses, and continued coverage through the longest applicable
limitations period under the Company&#8217;s directors and officers insurance policies, all such payments to be made within 60 days of
the date of termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above
the Company may terminate Mr.&#160;Shemesh&#8217;s employment at any time, immediately, for Cause, upon written notice to Mr.&#160;Shemesh.
If Mr.&#160;Shemesh&#8217;s employment is terminated for Cause, he shall be entitled to receive (i)&#160;the unpaid portion of his base
salary then in effect accrued through the effective date of the termination of his employment, and (ii)&#160;payment for any unused vacation
days which have accrued through the effective date of the termination of his employment, in each case to be paid within 30 days after
such effective date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a &#8220;<i>Transaction</i>&#8221;&#8203;
occurs during Mr.&#160;Shemesh&#8217;s employment, regardless of whether Mr.&#160;Shemesh&#8217;s employment is terminated, Mr.&#160;Shemesh
shall receive payment of the termination benefits described above as if his employment had been terminated on the effective date of the
Transaction. Following the Transaction, Mr.&#160;Shemesh shall not be entitled to receive such termination benefits upon a future termination
of his employment; provided that he shall remain eligible to receive (i)&#160;any accrued benefits upon any such subsequent termination
and (ii)&#160;cash payments, paid in periodic installments in accordance with the Company&#8217;s usual payroll practices for a period
of 18 months, equal to the cost the Company would have incurred had Mr.&#160;Shemesh continued group medical, dental, vision and/or prescription
drug benefit coverage for himself and/or his eligible dependents under any Company sponsored group health plan covering Mr.&#160;Shemesh
and his eligible dependents at the time of the termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards as of December&#160;31, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information concerning option awards and stock awards held by our Named Executive Officers as of December&#160;31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td colspan="13" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
                                            Awards</b></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"><b>Name</b></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of Shares or<br /> Units of Stock That<br /> Have Not <br /> Vested (#)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><sup>&#160;</sup>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
                                            Value of<br /> Shares or Units of<br /> Stock That Have <br /> </b></span><b><span style="font-size: 10pt">&#160;&#160;Not
                                            Vested ($)<sup>(1)</sup></span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><b>Equity
                                            Incentive Plan Awards:<br /> Number of Unearned Shares, <br /> Units or Other Rights That Have
<br />
Not Vested (#)</b></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
                                            Incentive Plan Awards: Market<br /> or Payout Value of Unearned Shares</b></span><b><span style="font-size: 10pt">,<br />
                                            Units or other rights That Have <br /> &#160;&#160;Not Vested ($)<sup>(1)</sup>&#160;&#160;</span></b></td><td style="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%; font-size: 10pt; text-align: left">Mr.Bentsur</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,759</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><sup>(2)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">725,693</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 25%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">120,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(3)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">900,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dr.Poradosu</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(2)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">362,993</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(3)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">450,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Mr.Shemesh</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,399</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(2)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">362,993</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><sup>(3)</sup>&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">450,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td>Market value is based on $ 7.50 per share, the closing price of our common
                                            stock on the Nasdaq Capital Market on December&#160;31, 2022, the last trading day of the
                                            fiscal year.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(2)</td><td>Reflects restricted stock awards granted upon the completion of a $15.3
                                            million financing round which will vest on June&#160;30, 2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(3)</td><td>&#160;Reflects restricted stock awards granted upon the completion of the
Company&#8217;s IPO which will vest in thirds on the next three anniversaries of the grant date, April&#160;1, 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D</b></span><b><span style="text-transform: uppercase">IRECTOR
COMPENSATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&#160;2022, our
directors adopted a Non-Employee Directors Compensation Plan. Our non-employee directors receive the following compensation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Cash Compensation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">$40,000
                                            annual retainer;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">$5,000 additional
                                            annual retainer for Compensation Committee membership;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">$5,000 additional
                                            annual retainer for Audit Committee membership;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">$15,000 additional
                                            annual retainer for the Audit Committee Chair; and</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">$15,000 additional
                                            annual retainer for the Compensation Committee Chair.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Equity Compensation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Initial
                                            Equity Grant: 29,250 options to purchase our common stock, which shares shall vest and become
                                            non-forfeitable in equal annual installments over three years, beginning on the first anniversary
                                            of the grant date, subject to the director&#8217;s continued service on the board of directors
                                            on such date.</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">Re-Election
                                            Equity Grant: Options having an estimated value of approximately $150,000, which shall vest
                                            and become non-forfeitable in equal annual installments over three years, beginning on the
                                            first anniversary of the grant date, subject to the director&#8217;s continued service on
                                            the board of directors on such date.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, each non-employee
director receives reimbursement for reasonable travel expenses incurred in attending meetings of our board of directors and meetings
of committees of our board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Director Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth the cash and other compensation we paid to the non-employee members of our Board of Directors for all services in all capacities
during 2022. Mr.&#160;Bentsur is the Chief Executive Officer of the Company and does not receive additional compensation for his service
on the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Name</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
    Earned<br />
    or Paid in <br /> &#160;Cash ($)<sup>(1)</sup></b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Option<br />
Awards<br />
($)<sup>(2)(3)</sup></b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br />
    &#160;&#160;&#160;&#160;($)&#160;&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">Kenneth Hoberman</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">55,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">135,138</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">190,138</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Matthew Kaplan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">45,833</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,138</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">180,971</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">James Oliviero</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">55,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135,138</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">190,138</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify">Represents
                                            cash retainer for serving on our Board and committees of the Board.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify">Reflects the aggregate grant date fair value of stock options granted
during the fiscal year calculated in accordance with FASB ASC Topic 718. Refer to Note 7 in the Notes to the Financial Statements included
in our Original Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 for information regarding the assumptions used
to value these awards.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify">All
                                            non-employee directors received a grant of 29,250 options for their initial equity grant
                                            during 2021. In addition, 15,000 options were granted to the non-employee directors on April&#160;1,
                                            2022 which vest one third on each anniversary date until 2025. All of these options remained
                                            outstanding on December&#160;31, 2022.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="har_004"></span>Item&#160;12.&#160;&#160;&#160;Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Security Ownership of Certain Beneficial Owners</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
information, as of March&#160;22, 2023, concerning the beneficial ownership of our common stock by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">each
                                            person we know to be the beneficial owner of more than 5% of our common stock;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">each of our current
                                            directors; and</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">each of our NEOs
                                            shown in our Summary Compensation Table.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ALL CURRENT DIRECTORS AND NEOS AS A GROUP</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March&#160;22, 2023,
there were 14,752,403 shares of our common stock outstanding. In order to calculate a stockholder&#8217;s percentage of beneficial ownership,
we include in the calculation those shares underlying options or warrants beneficially owned by that stockholder that are vested or that
will vest within 60 days of March&#160;22, 2023. Shares of restricted stock are deemed to be outstanding. Options or warrants held by
other stockholders that are not attributed to the named beneficial owner are disregarded in this calculation. Beneficial ownership is
determined in accordance with the rules&#160;of the SEC and includes voting or investment power with respect to the shares of our common
stock. Unless we have indicated otherwise, each person named in the table below has sole voting power and investment power for the shares
listed opposite such person&#8217;s name, except to the extent authority is shared by spouses under community property laws. The address
of all directors and executive officers is c/o Nuvectis Pharma,&#160;Inc., 1 Bridge Plaza, Suite&#160;275, Fort Lee, NJ 07024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common
    Stock Beneficially Owned</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares<br /> and Nature of <br /> Beneficial <br /> &#160;&#160;Ownership&#160;&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage<br />
    of Total <br /> Common <br /> &#160;&#160;&#160;&#160;Stock&#160;&#160;&#160;&#160;</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Name and Address of Beneficial Owner:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ron
    Bentsur <sup>(1)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,801,340</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">18.99</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrique
    Poradosu <sup>(2)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,149,920</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shay
    Shemesh <sup>(3)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,138,556</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7.72</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Micahel Carson</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Hoberman <sup>(4)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">69,890</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    Kaplan <sup>(5)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">50,510</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Oliviero <sup>(6)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,578</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify">All executive officers and directors
    as a group</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,243,894</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">35.54</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: justify">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">5% or Greater Stockholders:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles
    Mosseri Marlio <sup>(7)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,380,176</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pontifax
    VI LP <sup>(8)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,379,360</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9.35</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    P. Peters 2012 Family Trust <sup>(9)</sup>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">947,658</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.42</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Represents beneficial
                                            ownership of less than 1%</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify">This
                                            excludes 96,759 shares of restricted stock granted to Mr.&#160;Bentsur on July&#160;27, 2021
                                            in connection with the closing of the $15.3 million Preferred A capital raise. These restricted
                                            shares vest on June&#160;30, 2023. This also excludes 120,000 shares of restricted stock
                                            granted to Mr.&#160;Bentsur on April&#160;1, 2022 in connection with his employee agreement.
                                            These shares vest over a 3-year period with 1/3 vesting on each anniversary date of the grant.&#160;
                                            This also excludes 210,000 shares of restricted stock granted to Mr.&#160;Bentsur on January&#160;12,
                                            2023.&#160; These shares vest over a 3-year period with 1/3 vesting on each anniversary date
                                            of the grant.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify">This
                                            excludes 48,399 shares of restricted stock granted to Dr.&#160;Poradosu on July&#160;27,
                                            2021 in connection with the closing of the $15.3 million Preferred A capital raise. These
                                            restricted shares vest on June&#160;30, 2023. This also excludes 60,000 shares of restricted
                                            stock granted to Dr.&#160;Poradosu on April&#160;1, 2022 in connection with his employee
                                            agreement. These shares vest over a 3-year period with 1/3 vesting on each anniversary date
                                            of the grant.&#160; This also excludes 115,000 shares of restricted stock granted to Dr.&#160;Poradosu
                                            on January&#160;12, 2023. These shares vest over a 3-year period with 1/3 vesting on each
                                            anniversary date of the grant.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify">This
                                            excludes 48,399 shares of restricted stock granted to Mr.&#160;Shemesh on July&#160;27, 2021
                                            in connection with the closing of the $15.3 million Preferred A capital raise. These restricted
                                            shares vest on June&#160;30, 2023. This also excludes 60,000 shares of restricted stock granted
                                            to Mr.&#160;Shemesh on April&#160;1, 2022 in connection with his employee agreement. These
                                            shares vest over a 3-year period with 1/3 vesting on each anniversary date of the grant.&#160;
                                            This also excludes 115,000 shares of restricted stock granted to Mr.&#160;Shemesh on January&#160;12,
                                            2023. These shares vest over a 3-year period with 1/3 vesting on each anniversary date of
                                            the grant.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify">Excludes
                                            16,380 shares owned by the Hoberman Descendants Trust, to which Mr.&#160;Hoberman disclaims
                                            ownership. On July&#160;19, 2021, Mr.&#160;Hoberman was granted 29,250 options vesting over
                                            a 3-year period, 1/3 each year, exercisable into common shares of the Company at a price
                                            of $3.05. 9,750 options will be exercisable within 60 days of March&#160;23, 2023 and were
                                            included in the beneficial ownership calculation. On April&#160;1, 2022 Mr.&#160;Hoberman
                                            was granted 15,000 options vesting over a 3-year period with 1/3 vesting on each anniversary
                                            date of the grant, exercisable into common shares of the Company at a price of $7.02.&#160;
                                            5,000 options will be exercisable within 60 days of March&#160;23, 2023 and were included
                                            in the beneficial ownership calculation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify">On
                                            September&#160;2, 2021, Mr.&#160;Kaplan was granted 29,250 options vesting over a 3-year
                                            period, 1/3 each year, exercisable into common shares of the Company at a price of $3.05.
                                            9,750 options will be exercisable within 60 days of March&#160;23, 2023 and were included
                                            in the beneficial ownership calculation.&#160; On April&#160;1, 2022 Mr.&#160;Kaplan was
                                            granted 15,000 options vesting over a 3-year period with 1/3 vesting on each anniversary
                                            date of the grant, exercisable into common shares of the Company at a price of $7.02.&#160;5,000
                                            options will be exercisable within 60 days of March&#160;23, 2023 and were included in the
                                            beneficial ownership calculation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify">On
                                            July&#160;6, 2021, Mr.&#160;Oliviero was granted 29,250 options vesting over a 3-year period,
                                            1/3 each year, exercisable into common shares of the Company at a price of $3.05. 9,750 shares
                                            will be exercisable within 60 days of June&#160;30, 2022 and were included in the beneficial
                                            ownership calculation. On April&#160;1, 2022 Mr.&#160;Oliviero was granted 15,000 options
                                            vesting over a 3-year period with 1/3 vesting on each anniversary date of the grant, exercisable
                                            into common shares of the Company at a price of $7.02.&#160; 5,000 options will be exercisable
                                            within 60 days of March&#160;23, 2023 and were included in the beneficial ownership calculation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify">The
                                            address of Charles Mosseri-Marlio is 27 Ripplevale Grove, London N1 1HS, UK. Share ownership
                                            reported above is based on a Form&#160;13G/A filed by Charles Mosseri-Marlio on January&#160;9,
                                            2023.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify">Pontifax
                                            Management 4 GP (2015) Ltd. is the general partner (the &#8220;General Partner&#8221;) of
                                            Pontifax VI GP L.P, the general partner of each of, Pontifax VI (Cayman) LP and Pontifax
                                            VI (Israel) LP (which are collectively referred to as &#8220;Pontifax VI LP&#8221;). Mr.&#160;Tomer
                                            Kariv holds approximately 51% of the share capital of the General Partner; as a result, Mr.&#160;Kariv
                                            may be deemed to exercise control over Pontifax VI LP. The remaining share capital is held
                                            by Mr.&#160;Ran Nussbaum. Mr.&#160;Kariv and Mr.&#160;Nussbaum disclaim beneficial ownership
                                            of all the reported shares and the inclusion of all shares herein shall not be deemed to
                                            be an admission of beneficial ownership of the reported shares except to the extent of their
                                            pecuniary interest therein.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify">Based
                                            solely on the information provided by such reporting person.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="har_005"></span>Item&#160;13.&#160;&#160;&#160;Certain Relationships
and Related Transactions, and Director Independence.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>RELATED-PERSON
TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since inception, we have
not been involved in a transaction or series of similar transactions that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">the
                                            amount involved exceeded or exceeds $120,000 or 1% of the average of our total assets as
                                            of December&#160;31, 2022 and 2021; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">any
                                            of our directors or executive officers, any holder of 5% of our capital stock or any member
                                            of their immediate family had or will have a direct or indirect material interest.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policies and Procedures for Transaction with
Related Persons</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors adopted
a written related person transaction policy, setting forth the policies and procedures for the review and approval or ratification of
related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities
Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were
or are to be a participant, where the amount involved exceeds $120,000 or 1% of the average of our total assets as of December&#160;31,
2022 and 2021 and a related person had or will have a direct or indirect material interest, including without limitation purchases of
goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees
of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked
to consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to those
that could be obtained in an arm&#8217;s length transaction with an unrelated third party and the extent of the related person&#8217;s
interest in the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that Kenneth Hoberman, Matthew Kaplan and James Oliviero are independent directors. In making this determination, our board
of directors applied the standards set forth in the rules&#160;of Nasdaq and in Rule&#160;10A-3 under the Exchange Act. Our board of
directors considered all relevant facts and circumstances known to it in evaluating the independence of these directors, including their
current and historical employment, any compensation we have given to them, any transactions we have with them, their beneficial ownership
of our capital stock, their ability to exert control over us, all other material relationships they have had with us and the same facts
with respect to their immediate families.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although there is no specific
policy regarding diversity in identifying director nominees, the board of directors seek the talents and backgrounds that would be most
helpful to us in selecting director nominees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="har_006"></span>Item&#160;14.&#160;&#160;&#160;Principal Accounting
Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents the aggregate fees billed to the Company
for professional services rendered by Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers
International Limited for the years ended December&#160;31, 2022 and 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022&#160;</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees<sup>(1)</sup>&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 10%; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,000</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 10%; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,000</span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-Related Fees<sup>(2)</sup></span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,100</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Fees</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,100</span></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,000</span></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 27px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees consist of fees
    billed for professional services rendered in connection with the audit of our annual financial statements included in our Original
    Annual Report on Form&#160;10-K for those two fiscal years, the review of our financial statements included in our Quarterly Reports
    on Form&#160;10-Q during those two fiscal years, and other services provided in connection with registration statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 27px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022, audit-related fees pertained to services rendered in connection with procedures required for filings with the SEC.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pre-Approval of Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit Committee has established
a policy setting forth the procedures under which services provided by our independent registered public accounting firm will be pre-approved
by our Audit Committee. The potential services that might be provided by our independent registered public accounting firm fall into
two categories:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">Services
                                            that are permitted, including the audit of our annual financial statements, the review of
                                            our quarterly financial statements, related attestations, benefit plan audits and similar
                                            audit reports, financial and other due diligence on acquisitions, and federal, state, and
                                            non-US tax services; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td style="text-align: justify">Services
                                            that may be permitted, subject to individual pre-approval, including compliance and internal-control
                                            reviews, indirect tax services such as transfer pricing and customs and duties, and forensic
                                            auditing.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Services that our independent
registered public accounting firm are prohibited from providing include such services as bookkeeping, certain human resources services,
internal audit outsourcing, and investment or investment banking advice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All proposed engagements
of our independent registered public accounting firm, whether for audit services or permissible non-audit services, are pre-approved
by the Audit Committee. We jointly prepare a schedule with our independent registered public accounting firm that outlines services which
we reasonably expect we will need from our independent registered public accounting firm and categorize them according to the classifications
described above. Each service identified is reviewed and approved or rejected by the Audit Committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="har_007"></span>PART&#160;IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;</b></span><b><span id="har_008"></span>15.&#160;&#160;&#160;Exhibits
and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><b>(a)</b></td><td style="text-align: justify"><b>Financial Statements.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The response to this portion of Item 15 is incorporated by reference
from the Original Filing into this Amendment No. 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><b>(b)</b></td><td style="text-align: justify"><b>Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amended and Restated Certificate of Incorporation of Nuvectis Pharma,&#160;Inc., filed as exhibit 3.1 to the Form&#160;8-K filed
    on February&#160;4, 2022 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma,&#160;Inc., filed as exhibit 3.3
    to the Form&#160;8-K filed on February&#160;4, 2022 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922011786/tm2134227d1_ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Bylaws of Nuvectis Pharma,&#160;Inc., filed as exhibit 3.2 to the Form&#160;8-K filed on February&#160;4, 2022 and incorporated
    herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921128180/tm2123577d9_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921128180/tm2123577d9_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Common Stock Certificate, filed as exhibit 4.1 to the Form&#160;S-1/A, filed on October&#160;21, 2021 and incorporated herein by
    reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921130769/tm2123577d12_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921130769/tm2123577d12_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Warrant, filed as exhibit 4.2 to the Form&#160;S-1/A filed on October&#160;28, 2021 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922004520/tm2134024d8_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922004520/tm2134024d8_ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Underwriter&#8217;s Warrant, filed as exhibit 4.2 to the Form&#160;S-1/A filed on January&#160;18, 2022 and incorporated herein by
    reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Preferred Investment Option, filed as exhibit 10.2 to the Form&#160;8-K filed on July&#160;29, 2022 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465922084332/tm2222131d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Pre-Funded Warrant, filed as exhibit 10.3 to the Form&#160;8-K filed on July&#160;29, 2022 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex4d6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex4d6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Securities of Nuvectis Pharma,&#160;Inc. filed as exhibit 4.6 to the Form&#160;10-K filed on March&#160;8, 2023 and incorporated
    herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021
    Global Equity Incentive Plan, filed as exhibit 10.1 to the Form&#160;S-1/A filed on October&#160;6, 2021 and incorporated herein
    by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement with Ron Bentsur, filed as exhibit 10.2 to the Form&#160;S-1/A filed on October&#160;6, 2021 and incorporated
    herein by reference. #</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement with Enrique Poradosu, filed as exhibit 10.3 to the Form&#160;S-1/A filed on October&#160;6, 2021 and incorporated
    herein by reference. #</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement with Shay Shemesh, filed as exhibit 10.4 to the Form&#160;S-1/A filed on October&#160;6, 2021 and incorporated
    herein by reference. #</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d3_ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement between Nuvectis Pharma,&#160;Inc. and CRT Pioneer Fund LP dated May&#160;19, 2021, filed as exhibit 10.5 to the Form&#160;S-1/A
    filed on October&#160;6, 2021 and incorporated herein by reference. **</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d6_ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000110465921123697/tm2123577d6_ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement between Nuvectis Pharma,&#160;Inc. and The University Court of the University of Edinburgh, dated August&#160;26, 2021,
    filed as exhibit 10.6 to the Form&#160;S-1/A filed on October&#160;6, 2021 and incorporated herein by reference. **</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex21d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex21d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    of subsidiaries of Nuvectis Pharma,&#160;Inc. filed as exhibit 21.1 to the Form&#160;10-K filed on March&#160;8, 2023 and incorporated
    herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000155837023003181/tmb-20221231x10k.htm#POWEROFATTORNEY_610454"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1875558/000155837023003181/tmb-20221231x10k.htm#POWEROFATTORNEY_610454"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney filed as exhibit 24.1 to the Form&#160;10-K filed on March&#160;8, 2023 and incorporated herein by reference.</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 20; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8%"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex31d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 91%"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex31d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2022 filed as exhibit 31.1 to the Form&#160;10-K
    filed on March&#160;8, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex31d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex31d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal
    Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2022 filed as exhibit 31.2 to the Form&#160;10-K filed
    on March&#160;8, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2310472d1_ex31-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2310472d1_ex31-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal
    Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2022. </span>*</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2310472d1_ex31-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.4</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="tm2310472d1_ex31-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. *</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex32d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex32d1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Principal Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 filed as exhibit 32.1 to the Form&#160;10-K
    filed on March&#160;8, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex32d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><a href="http://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231xex32d2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 filed as exhibit 32.2 to the Form&#160;10-K
    filed on March&#160;8, 2023 and incorporated herein by reference.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Schema Linkbase Document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Labels Linkbase Document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page&#160;Interactive Data File - the cover page&#160;interactive data file does not appear in the Interactive Data File because
    its XBRL tags are embedded within the Inline XBRL document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td>Filed herewith.</td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td>Certain portions of this exhibit have
                                            been omitted pursuant to Item&#160;601(b)(10)&#160;of Regulation S-K.</td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td>Management Compensation Arrangement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#160;16.</b></span><b><span id="har_009"></span>&#160;&#160;&#160;Form&#160;10-K
Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected not to provide summary
information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21; Value: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="har_010"></span>Signatures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Fort Lee, State of New Jersey, on this 27<sup>th</sup> day of March&#160;2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nuvectis Pharma,&#160;Inc.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ron Bentsur</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Ron Bentsur</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chairman, Chief Executive Officer and President</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OkrNqLwrKYksQiK6XXSMJd2R2e3vkXrLNiUaBobhnO8cIQYipbWqkeG8zDM4YtPW0iLkWCGjLtA5ks02BndzvChjWWrbvT8wIcegYybDYFoUTum8d2WwjMEfj8JoFI7Bn8fRDBY74X31hHSlStRWyRqkLuHA1LJCK/nVJxzlkzQ1r67rhGwU6RiCod/Lbwj9IIQ93eWD+GogyxLhDbrxRMp0a781N2OpgVWNjesyPfpf7wN2XUmt -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>2
<FILENAME>tm2310472d1_ex31-3.htm
<DESCRIPTION>EXHIBIT 31.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;31.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Ron Bentsur certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;I have reviewed this Amendment No.&nbsp;1
to the Annual Report on Form&nbsp;10-K of Nuvectis Pharma,&nbsp;Inc. (the registrant); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Dated: March&nbsp;27, 2023</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Ron Bentsur</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Ron Bentsur</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chairman, Chief Executive Officer and President</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.4
<SEQUENCE>3
<FILENAME>tm2310472d1_ex31-4.htm
<DESCRIPTION>EXHIBIT 31.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;31.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Michael J. Carson, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;I have reviewed this Amendment No.&nbsp;1
to the Annual Report on Form&nbsp;10-K of Nuvectis Pharma,&nbsp;Inc. (the registrant); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March&nbsp;27, 2023</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font-size: 10pt; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael J. Carson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Michael J. Carson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Vice President of Finance</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial and Accounting Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nvct-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17cc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaeLKbOdzZR+6YkxtmB3bXn6XyEkI/DPwSCIhQyWYSYA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:nvct="http://nuvectis.com/20221231" elementFormDefault="qualified" targetNamespace="http://nuvectis.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nuvectis.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nvct-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nvct-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nvct-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17cc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nvct-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17cc -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nuvectis.com/role/Cover" xlink:href="nvct-20221231.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nuvectis.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139647334142512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NUVECTIS PHARMA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001875558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-2405608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Bridge Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fort Lee<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">614-3150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,752,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers International Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>tm2310472d1_10ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvct-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875558</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875558</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875558</identifier>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0001875558</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-12-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-01-01to2022-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-12-31">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-12-31">001-41264</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">NUVECTIS PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-12-31">86-2405608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-12-31">1 Bridge Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-12-31">Suite     275</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-12-31">Fort Lee</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-12-31">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-12-31">07024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-12-31">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-12-31">614-3150</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-12-31">Common Stock, par value $0.00001 per</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-12-31">NVCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-01-01to2022-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-01-01to2022-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-12-31">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2022-01-01to2022-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2022-12-30" decimals="-5" unitRef="USD">64000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-03-22" decimals="INF" unitRef="Shares">14752403</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2022-01-01to2022-12-31">PricewaterhouseCoopers International Limited</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-01to2022-12-31">Tel-Aviv, Israel</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="From2022-01-01to2022-12-31">1309</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=0V)&&;M^E]@>=-HO,X,%Q,Y[6B>#4-5+ONN9SJ&=7C X1BY[!\W@OE8S(T
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #@0WM6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .!#
M>U8V)*1&[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .!#>U:97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ X$-[5F\':D+'
M!P  /#,  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .!#>U:R]\)O[@(  (D.   -              "
M 0L0  !X;"]S='EL97,N>&UL4$L! A0#%     @ X$-[5I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  )P7      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>38</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2310472d1_10ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nuvectis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  tm2310472d1_10ka.htm 24</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K/A" original="tm2310472d1_10ka.htm">tm2310472d1_10ka.htm</File>
    <File>nvct-20221231.xsd</File>
    <File>nvct-20221231_lab.xml</File>
    <File>nvct-20221231_pre.xml</File>
    <File>tm2310472d1_ex31-3.htm</File>
    <File>tm2310472d1_ex31-4.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2310472d1_10ka.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 38
   },
   "contextCount": 3,
   "dts": {
    "inline": {
     "local": [
      "tm2310472d1_10ka.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvct-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvct-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvct-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 63,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 0,
   "keyStandard": 38,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nvct",
   "nsuri": "http://nuvectis.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2310472d1_10ka.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://nuvectis.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2310472d1_10ka.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nuvectis.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-23-036896-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-036896-xbrl.zip
M4$L#!!0    ( .!#>U9T4YF_.0,  /8+   1    ;G9C="TR,#(R,3(S,2YX
M<V2U5MM2VS 0?6YG^@^J7QG%<5*@A 2&0NED&@HEY?K24>1-T.!(1I)SZ==7
MDNTD)"8DH?63O'O.V5UI5W;]<-2/T "D8H(WO*!4]A!P*D+&>PWOJHV/VL?-
MIH<.#SZ\1^:I?\08G3*(PAHZ$10W>5?LHQ^D#S7T#3A(HH7<1]<D2JQ%G+((
M)#H6_3@"#<:11JJA[5*P2RG"> 7A:^"AD%>7S8GP@]:QJOG^<#@L<3$@0R$?
M58F*_FJ";4UTHB9JY5$Y>U:CGS%%)^0M<K0]W!U=LML>\,])BU3OZ0V!UO?.
M>?CG_G)KY^YQI/M?JIU;OG,[_OK8]$\NAF93'WZ.;^[:=T=IR+JB#] GR)P&
M5PW/UI>5-ZR6A.SYE7(Y\&_/6FV'\U)@;10Q_E@$#_;V]GSGS:$+R%%'1KET
MU;?N#E$P439>M@3/N-*$TV?X4$\(L^!M/W4^@[)"Z$X*93DTA#F< EKJB8%O
M' 9?"9X^Y=!$X1XA\03>):KC9#.'@^-R@*M!3E%2+\*-L1B*]3@&54A(704T
M/J#3$#P9 -7,]:G%5H**14($?>#Z5,C^"71)$AG&4T(BUF40>D@3V0-M&T_%
MA,(K:GGW$LZ%:7(S:IG%VN*8F2XVAG=U>]PU*2+X93)'=F'&JUC;.OUC8>X(
M#[&PX:5+JV(TG4X(7<:9"Y;-48"PG9K$%F:6CE+WY\$S$HF"\)P?N'4L01F>
MR[YE#!DQ@[Q HB2B2;0>9YI*(24SY+LTW;=\5BZAB]R,U>SY-SS%[#7G9;8'
M"=V&9SL Y\?SVY16,IV10ZSTDAES.S^_&UG@7()(NJ"R< <8$1&#U,PTZ<R@
MIZDS;>D7,V&0C:,\Y/^+DB/26;=D0X'H/];:LOJS168#XD\G)'N?GZ*Z*5=(
MC?C"."Z[(=.[O26HDUI"L6\XYV%KPD'%7">ED0JGF:Z3Q'0'UDLBYVV0Q(OW
M=%$&ZF6"7>)TN6KHI7?^TO"%3!\BK7(+GFIMDL[B%^(-^3BQ#1)Z=MBAEKX5
MLM)EJU-9DM1K3/>N-FH1*A*NY=A5N&*3S%+R%[<=:Y_,_-=^M4/)6>F!V!^
M-S1'\?_#IHF\W!IU/]4TR[]02P,$%     @ X$-[5OMJ;(&*"P  :H\  !4
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M.K=< #9U, Q10&38G0%H5&)4JA&7>X/CAB4;S%Z72=33;;2%;O& C.I\F*J
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M>0"FECY$I""3O6#)0-]\+4FTY?WEZ_1H=9<4J>W$LRUQUC\!YNK>R2@/@@_
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M-C>G?;I9_QNW^K>YQ;_U%F=XS]8>/56KU^KW>7Q[]V\)& ?KA_\[\@""HP,
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M73)N\%83-2E)53WE(DZBW8 '9%/(;,& 6XZXW,2D_(E9]\6NQ%N+>N;?-.4
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MYSH2@ 2G'JICIQ%S&LC"\P>.)V62F/=O#*B4YN_1!*( 0V"JZON];P7=JKC
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M6&)L4^&E\*1/E]&\%7X &@I85W( "$.;!1)#>K(\>S2F&N7/H5S"4=6HH]$
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M;0CL>]@;IADP]=E.8,<#7![&&S#8Y"'M.,2NE#- ^SP< ZT4/PPSXC,3C79
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M*2&ID_KZ)>FB. DQ3.<M'FBWUP0QFY.P%:V:#>$M5,$&"ZL@ R2'#+QCPC&
MTD5Q85;OPBD/0\,Y1.)D[7X(7[0PTT_V>MR(QX0@R4^B8WIA=LN4%PYL*93Z
MBZ8&7Q47%$!),R(*6V/H=Z<.JK1,/^OCNM5950')E%2J*-^'[@P .@>($V?
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MA _D+RE4B$@<)![U/0]03$U@L3S/P1&G5F!T"4Y97D6TAH'C*A[,)S _ZIF
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M!VO!C5.WX/C;^S)YBNY0+D.UA2&ND*)-%(MXX?1(+[)<4-6[(U*-7E;4G;X
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MU:X:3(CH>02B.^].XRC10C/>5F0"9 OF)@4('I[Y1!Q;%YF^K=P0/Y016_"
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MTE.K7UOI8:Z+=X\N82MWPIPHL*ZDFS3;3ELB8G]&;*M,$:.!E'!:EZ$.8A7
M';%3WT8-&6VM\=SRU!+W%)SL64(7BRAV+UT@3)^,<^FNEH*JTWZ?6Z93O;[I
M!,*)7=0#5/& C#=)64P:-=YKU$A]4M3A$QBEX@_<,13^;5NHV$6.A'6H/K44
M>4A;7ZH2=NHOBWIXWY&]\7Z%N>%#M(FN+WG>4#(>(+$)LEOKJ<Z=:G& \"R
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MK<8"X <<*:X\?KAX0\VK:*J]75AGWA'F7Q+B6MEQ=BU5)IW/\\9YV+E%SCP
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M: ,  &YV8W0M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( .!#>U9U#3P
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M  !T;3(S,3 T-S)D,5]E>#,Q+30N:'1M4$L%!@     &  8 CP$  -24
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
